BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) dropped 3.8% during trading on Tuesday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The firm’s fifty day moving average price is C$10.60 and its 200 day moving average price is C$10.60. The firm has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 128.68 and a current ratio of 129.63.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
